Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments

Pandemic of coronavirus disease (COVID-19) is still pressing the healthcare systems worldwide. Thus far, the lack of available COVID-19-targeted treatments has led scientists to look through drug repositioning practices and exploitation of available scientific evidence for potential efficient drugs...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Marios Spanakis, Athina Patelarou, Evridiki Patelarou, Nikolaos Tzanakis
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	drug-drug interactions COVID-19 ADRs healthcare personnel nursing personnel respiratory diseases Medicine R
Acceso en línea:	https://doaj.org/article/c8e11f03c1724e42be50bdc78ade76c4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c8e11f03c1724e42be50bdc78ade76c4
record_format	dspace
spelling	oai:doaj.org-article:c8e11f03c1724e42be50bdc78ade76c42021-11-11T16:47:08ZDrug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments10.3390/ijerph1821117111660-46011661-7827https://doaj.org/article/c8e11f03c1724e42be50bdc78ade76c42021-11-01T00:00:00Zhttps://www.mdpi.com/1660-4601/18/21/11711https://doaj.org/toc/1661-7827https://doaj.org/toc/1660-4601Pandemic of coronavirus disease (COVID-19) is still pressing the healthcare systems worldwide. Thus far, the lack of available COVID-19-targeted treatments has led scientists to look through drug repositioning practices and exploitation of available scientific evidence for potential efficient drugs that may block biological pathways of SARS-CoV-2. Till today, several molecules have emerged as promising pharmacological agents, and more than a few medication protocols are applied during hospitalization. On the other hand, given the criticality of the disease, it is important for healthcare providers, especially those in COVID-19 clinics (i.e., nursing personnel and treating physicians), to recognize potential drug interactions that may lead to adverse drug reactions that may negatively impact the therapeutic outcome. In this review, focusing on patients with respiratory diseases (i.e., asthma or chronic obstructive pulmonary disease) that are treated also for COVID-19, we discuss possible drug interactions, their underlying pharmacological mechanisms, and possible clinical signs that healthcare providers in COVID-19 clinics may need to acknowledge as adverse drug reactions due to drug-drug interactions.Marios SpanakisAthina PatelarouEvridiki PatelarouNikolaos TzanakisMDPI AGarticledrug-drug interactionsCOVID-19ADRshealthcare personnelnursing personnelrespiratory diseasesMedicineRENInternational Journal of Environmental Research and Public Health, Vol 18, Iss 11711, p 11711 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	drug-drug interactions COVID-19 ADRs healthcare personnel nursing personnel respiratory diseases Medicine R
spellingShingle	drug-drug interactions COVID-19 ADRs healthcare personnel nursing personnel respiratory diseases Medicine R Marios Spanakis Athina Patelarou Evridiki Patelarou Nikolaos Tzanakis Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
description	Pandemic of coronavirus disease (COVID-19) is still pressing the healthcare systems worldwide. Thus far, the lack of available COVID-19-targeted treatments has led scientists to look through drug repositioning practices and exploitation of available scientific evidence for potential efficient drugs that may block biological pathways of SARS-CoV-2. Till today, several molecules have emerged as promising pharmacological agents, and more than a few medication protocols are applied during hospitalization. On the other hand, given the criticality of the disease, it is important for healthcare providers, especially those in COVID-19 clinics (i.e., nursing personnel and treating physicians), to recognize potential drug interactions that may lead to adverse drug reactions that may negatively impact the therapeutic outcome. In this review, focusing on patients with respiratory diseases (i.e., asthma or chronic obstructive pulmonary disease) that are treated also for COVID-19, we discuss possible drug interactions, their underlying pharmacological mechanisms, and possible clinical signs that healthcare providers in COVID-19 clinics may need to acknowledge as adverse drug reactions due to drug-drug interactions.
format	article
author	Marios Spanakis Athina Patelarou Evridiki Patelarou Nikolaos Tzanakis
author_facet	Marios Spanakis Athina Patelarou Evridiki Patelarou Nikolaos Tzanakis
author_sort	Marios Spanakis
title	Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
title_short	Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
title_full	Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
title_fullStr	Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
title_full_unstemmed	Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
title_sort	drug interactions for patients with respiratory diseases receiving covid-19 emerged treatments
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/c8e11f03c1724e42be50bdc78ade76c4
work_keys_str_mv	AT mariosspanakis druginteractionsforpatientswithrespiratorydiseasesreceivingcovid19emergedtreatments AT athinapatelarou druginteractionsforpatientswithrespiratorydiseasesreceivingcovid19emergedtreatments AT evridikipatelarou druginteractionsforpatientswithrespiratorydiseasesreceivingcovid19emergedtreatments AT nikolaostzanakis druginteractionsforpatientswithrespiratorydiseasesreceivingcovid19emergedtreatments
_version_	1718432264742764544

Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments

Ejemplares similares